Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Indiana University School of Medicine |
---|---|
Information provided by: | Indiana University |
ClinicalTrials.gov Identifier: | NCT00392275 |
Based on previous results with eyes without filtering blebs, the aqueous concentrations of ofloxacin and levofloxacin will exceed the concentration of ciprofloxacin after either topical or topical plus oral administration.
Condition | Intervention | Phase |
---|---|---|
Cataract |
Drug: Ofloxacin 0.3% Drug: Ciprofloxacin 0.3% Drug: Levofloxacin 0.5% Drug: Ofloxacin 400mg Drug: Ciprofloxacin 400mg Drug: Levofloxacin 250mg |
Phase IV |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Single Blind, Active Control, Parallel Assignment, Bio-availability Study |
Official Title: | Penetrance of Third Generation Fluoroquinolones in Eyes With Functioning Filtering Blebs |
Estimated Enrollment: | 48 |
Study Start Date: | November 2002 |
Study Completion Date: | May 2006 |
The purpose of this study is to assay human aqueous for concentrations of ofloxacin, ciprofloxacin and levofloxacin after topical or combined topical and oral administration in eyes with filtering blebs.
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Any subject who is already scheduled to have cataract surgery performed will qualify for participation with the exception of the following exclusion criteria:
United States, Indiana | |
Indiana University Hospital | |
Indianapolis, Indiana, United States, 46202 | |
Wishard Memorial Hospital | |
Indianapolis, Indiana, United States, 46202 | |
Richard L Rodeboush VA Medical Center | |
Indianapolis, Indiana, United States, 46202 |
Principal Investigator: | Louis B Cantor, MD | Indiana University |
Study ID Numbers: | 0208-29 |
Study First Received: | October 23, 2006 |
Last Updated: | December 21, 2007 |
ClinicalTrials.gov Identifier: | NCT00392275 |
Health Authority: | United States: Institutional Review Board |
Cataract Aqueous absorption Funtioning Filtering Blebs |
Pathological Conditions, Anatomical Ciprofloxacin Fluoroquinolones Skin Diseases, Vesiculobullous Skin Diseases |
Eye Diseases Cataract Ofloxacin Lens Diseases Blister |
Anti-Bacterial Agents Anti-Infective Agents Molecular Mechanisms of Pharmacological Action Therapeutic Uses Anti-Infective Agents, Urinary |
Enzyme Inhibitors Renal Agents Pharmacologic Actions Nucleic Acid Synthesis Inhibitors |